SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Q3 2024 Earnings Call November 12, 2024 8:30 AM ET

Company Participants

Kim Diamond - Vice President, Corporate Communications
Saqib Islam - Chief Executive Officer
Bhavesh Ashar - Chief Commercial Officer
Jim Cassidy - Chief Medical Officer
Francis Perier - Chief Financial Officer
Badreddin Edris - Chief Operating Officer

Conference Call Participants

Anupam Rama - JPMorgan
Peter Lawson - Barclays
Corinne Johnson - Goldman Sachs
David Nierengarten - Wedbush Securities
Alec Stranahan - Bank of America

Operator

Good morning. My name is Tanya, and I will be your conference operator today. At this time, I would like to welcome everyone to the SpringWorks Therapeutics Third Quarter 2024 Earnings Conference Call. [Operator Instructions] Thank you.

I would now like to turn the conference over to Kim Diamond, Vice President of Corporate Communications at SpringWorks Therapeutics. Kim, you may now begin the conference.

Kim Diamond

Thank you, and good morning, everyone. Welcome to the SpringWorks Therapeutics third quarter 2024 earnings conference call. This morning, we issued a press release, which outlines our financial and operational results for the third quarter. You can access the press release as well as the slides that we will be presenting today by going to the Investors & Media section of our website at www.springworkstx.com.

Joining me today are Saqib Islam, Chief Executive Officer; Bhavesh Ashar, Chief Commercial Officer; Dr. Jim Cassidy, Chief Medical Officer; Francis Perier, Chief Financial Officer; and Dr. Badreddin Edris, Chief Operating Officer.

Before we begin, I would like to remind you that some of the statements made during the call today are forward-looking statements that are subject to a number of risks and uncertainties. These may cause our actual results to differ materially, including those described in our reports filed with the SEC. You are cautioned not to place any undue reliance on these forward-looking statements, and SpringWorks disclaims any obligation to update such statements.

I will now turn the call over to Saqib.

Saqib Islam

Thank you, Ken, and thank you all for joining this morning. I’m pleased to share our third quarter results as well as an update on how we are delivering on our objective to make a profound impact on the lives of patients with devastating diseases.

Starting with OGSIVEO, for patients with desmoid tumors, we are very pleased with the continued strong momentum of our U.S. launch. In the third quarter, we reported $49.3 million in net product revenue, which represents a 23% growth quarter-over-quarter. This strong and steady growth is driven by robust demand, both from new patient starts as well as existing patients who are continuing to experience meaningful antitumor activity and substantial improvements in our quality of life on OGSIVEO. As we approach 1 year mark of our launch, we are very pleased with our progress in making OGSIVEO the standard of care systemic therapy for patients with desmoid tumors.